This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and ...

Richter transformation with CNS involvement in CLL patients results in poor prognosis and limited survival, with a median overall survival of 13 months. Treatment strategies for RT-CNS are often ...

Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.

Cardiovascular comorbidities were equally prevalent in full-dose and reduced-dose groups, suggesting well-controlled cardiovascular disease need not contraindicate standard dosing.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. I think this is one of the most exciting ...

A novel Calquence regimen demonstrated improved outcomes in certain patients with chronic lymphocytic leukemia. A treatment combination of Calquence (acalabrutinib) plus Venclexta (venetoclax) with or ...

Patients with chronic lymphocytic leukemia had better survival when treated with Calquence during earlier lines of therapy. Patients with chronic lymphocytic leukemia (CLL) who received Calquence ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...

Data source was SEER-Medicare, a population-based registry of adults age 65 years and older with cancer. We included all incident cases of NHL diagnosed during 2008-2017 who met study inclusion ...